US6849708B1
(en)
*
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US7138486B2
(en)
*
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US6852690B1
(en)
|
1995-08-22 |
2005-02-08 |
Amylin Pharmaceuticals, Inc. |
Method and composition for enhanced parenteral nutrition
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6277819B1
(en)
*
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
CN1209166C
(zh)
*
|
1998-06-12 |
2005-07-06 |
埃米林药品公司 |
含有与胰高血糖素样肽1的受体结合的化合物的组合物的制药用途
|
US6613785B2
(en)
|
1998-07-21 |
2003-09-02 |
Smithkline Beecham Plc |
Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
|
MA26662A1
(fr)
*
|
1998-07-21 |
2004-12-20 |
Smithkline Beecham Plc |
Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
|
AP2001002036A0
(en)
*
|
1998-07-21 |
2001-03-31 |
Smithkline Beecham Plc |
Use of glucose uptake enhancer for reducing apoptosis.
|
MY155270A
(en)
*
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
EP1652531A1
(en)
*
|
1998-09-24 |
2006-05-03 |
Eli Lilly & Company |
Use of GLP-1 or Analogues in Treatment of Stroke
|
US6284725B1
(en)
*
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
EA003922B1
(ru)
|
1999-05-17 |
2003-10-30 |
Конджачем, Инк. |
Продолжительно действующие инсулинотропные пептиды
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
JP4713798B2
(ja)
|
1999-06-29 |
2011-06-29 |
マンカインド コーポレイション |
ペプチドおよびタンパク質の薬学的因子の精製および安定化
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US20060160740A1
(en)
*
|
1999-10-21 |
2006-07-20 |
Suad Efendic |
Use of GLP-1 or analogs in treatment of stroke
|
JP2003532691A
(ja)
*
|
2000-05-05 |
2003-11-05 |
ノボ ノルディスク アクティーゼルスカブ |
重症疾患神経障害
|
DE60134403D1
(de)
*
|
2000-05-19 |
2008-07-24 |
Amylin Pharmaceuticals Inc |
Behandlung des akuten koronaren syndroms mit glp-1
|
JP4480329B2
(ja)
*
|
2000-10-20 |
2010-06-16 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
Glp−1ペプチドによる冬眠心筋および糖尿病性心筋症の治療
|
WO2002047716A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
CA2462543A1
(en)
*
|
2001-10-01 |
2003-04-10 |
Eli Lilly And Company |
Glucagon-like peptides (glp-1) and treatment of respiratory distress
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
US20030199445A1
(en)
*
|
2002-02-07 |
2003-10-23 |
Knudsen Lotte Bjerre |
Use of GLP-1 compound for treatment of critically ill patients
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
DE60335608D1
(de)
*
|
2002-02-27 |
2011-02-17 |
Pharmain Corp |
Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
|
US20050260259A1
(en)
*
|
2004-04-23 |
2005-11-24 |
Bolotin Elijah M |
Compositions for treatment with glucagon-like peptide, and methods of making and using the same
|
US7635463B2
(en)
*
|
2002-02-27 |
2009-12-22 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials
|
EP1494732B1
(en)
|
2002-03-20 |
2008-01-30 |
MannKind Corporation |
Inhalation apparatus
|
EP1494704A1
(en)
*
|
2002-04-04 |
2005-01-12 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
US7192922B2
(en)
*
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
EP1610811A4
(en)
*
|
2002-12-17 |
2008-03-26 |
Amylin Pharmaceuticals Inc |
PREVENTING AND TREATING CARDIAC ERRORS
|
WO2004094823A2
(en)
|
2003-04-23 |
2004-11-04 |
Biovalve Technologies, Inc. |
Hydraulically actuated pump for long duration medicament administration
|
ES2383752T3
(es)
|
2003-05-15 |
2012-06-26 |
Trustees Of Tufts College |
Analogos estables de GLP-1
|
CN1802386B
(zh)
|
2003-06-12 |
2010-12-15 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN1961000B
(zh)
|
2004-02-11 |
2011-05-04 |
安米林药品公司 |
具有可选择特性的杂合多肽
|
PT2100904E
(pt)
|
2004-04-23 |
2010-09-24 |
Conjuchem Biotechnologies Inc |
Fase sólida para utilização num método para a purificação de conjugados de albumina
|
US9089636B2
(en)
*
|
2004-07-02 |
2015-07-28 |
Valeritas, Inc. |
Methods and devices for delivering GLP-1 and uses thereof
|
KR101273120B1
(ko)
|
2004-08-20 |
2013-06-13 |
맨카인드 코포레이션 |
다이케토피페라진 합성의 촉매 작용
|
KR20130066695A
(ko)
|
2004-08-23 |
2013-06-20 |
맨카인드 코포레이션 |
약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
|
EP1838336A2
(en)
*
|
2004-12-24 |
2007-10-03 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
CA2597649A1
(en)
*
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
US8946149B2
(en)
*
|
2005-04-11 |
2015-02-03 |
Amylin Pharmaceuticals, Llc |
Use of exendin and analogs thereof to delay or prevent cardiac remodeling
|
JP2008536881A
(ja)
*
|
2005-04-21 |
2008-09-11 |
ガストロテック・ファルマ・アクティーゼルスカブ |
Glp−1分子と制吐剤との医薬製剤
|
PL1881850T3
(pl)
|
2005-05-13 |
2011-03-31 |
Lilly Co Eli |
Pegylowane związki GLP-1
|
KR20080028981A
(ko)
|
2005-06-30 |
2008-04-02 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Glp-1 약학 조성물
|
WO2007027344A2
(en)
*
|
2005-07-29 |
2007-03-08 |
Ziopharm Oncology, Inc. |
Compounds and methods for the treatment of cancer
|
CA2617649A1
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
IN2014DN09128A
(zh)
|
2005-09-14 |
2015-07-10 |
Mannkind Corp |
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
KR101872061B1
(ko)
*
|
2005-12-19 |
2018-06-27 |
파마인 코포레이션 |
치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법
|
US20070269863A1
(en)
*
|
2005-12-22 |
2007-11-22 |
Bridon Dominique P |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
BRPI0707991B8
(pt)
|
2006-02-22 |
2021-05-25 |
Mannkind Corp |
métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
|
US7914499B2
(en)
|
2006-03-30 |
2011-03-29 |
Valeritas, Inc. |
Multi-cartridge fluid delivery device
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
PE20080840A1
(es)
*
|
2006-09-13 |
2008-08-27 |
Smithkline Beecham Corp |
Metodos para administrar agentes hipoglucemiantes de larga duracion
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
CA2703234C
(en)
*
|
2007-10-24 |
2021-10-26 |
Mannkind Corporation |
An inhalable dry powder formulation comprising glp-1 for use by pulmonary inhalation
|
BRPI0818872A2
(pt)
*
|
2007-10-24 |
2015-05-05 |
Mannkind Corp |
Método para prevenir efeitos adversos por glp-1
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
US20090176892A1
(en)
|
2008-01-09 |
2009-07-09 |
Pharmain Corporation |
Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
CN109568740B
(zh)
|
2008-06-13 |
2022-05-27 |
曼金德公司 |
干粉吸入器和用于药物输送的系统
|
CA2727147A1
(en)
|
2008-06-17 |
2009-12-23 |
Otsuka Chemical Co., Ltd. |
Glycosylated glp-1 peptide
|
ES2904623T3
(es)
|
2008-06-20 |
2022-04-05 |
Mannkind Corp |
Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
|
TWI494123B
(zh)
|
2008-08-11 |
2015-08-01 |
Mannkind Corp |
超快起作用胰島素之用途
|
EP2163243A1
(en)
*
|
2008-09-12 |
2010-03-17 |
Biocompatibles UK Limited |
Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
|
CN102149411A
(zh)
|
2008-09-12 |
2011-08-10 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
AU2009293019A1
(en)
|
2008-09-19 |
2010-03-25 |
Tandem Diabetes Care Inc. |
Solute concentration measurement device and related methods
|
CA2740685C
(en)
|
2008-10-17 |
2018-09-11 |
Sanofi-Aventis Deutschland Gmbh |
Combination of an insulin and a glp-1 agonist
|
PT2373681T
(pt)
|
2008-12-10 |
2017-04-11 |
Glaxosmithkline Llc |
Composições farmacêuticas de albiglutida
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
EP2216042A1
(en)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP-1 analogues pharmaceutical compositions
|
PL2405963T3
(pl)
|
2009-03-11 |
2014-04-30 |
Mannkind Corp |
Urządzenie, układ i sposób pomiaru oporu inhalatora
|
US8614185B2
(en)
|
2009-05-04 |
2013-12-24 |
Centocor Ortho Biotech Inc. |
Fusion proteins of alpha-MSH derivatives and Fc
|
WO2010129248A1
(en)
|
2009-05-06 |
2010-11-11 |
Centocor Ortho Biotech Inc. |
Melanocortin receptor binding conjugates
|
KR101875969B1
(ko)
|
2009-06-12 |
2018-07-06 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
US8758323B2
(en)
|
2009-07-30 |
2014-06-24 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
US8642548B2
(en)
*
|
2009-08-07 |
2014-02-04 |
Mannkind Corporation |
Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
AU2010312655A1
(en)
|
2009-10-30 |
2012-05-03 |
Glytech, Inc. |
Glycosylated form of antigenic GLP-1 analogue
|
EP2496295A1
(en)
|
2009-11-03 |
2012-09-12 |
MannKind Corporation |
An apparatus and method for simulating inhalation efforts
|
JP5973918B2
(ja)
|
2009-11-13 |
2016-08-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト及びメチオニンを含む薬学的組成物
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
NZ603169A
(en)
|
2010-04-27 |
2015-02-27 |
Zealand Pharma As |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
US8691763B2
(en)
|
2010-05-04 |
2014-04-08 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
KR20130117755A
(ko)
|
2010-06-21 |
2013-10-28 |
맨카인드 코포레이션 |
건조 분말 약물 운반 시스템 및 방법
|
RU2013103763A
(ru)
|
2010-07-02 |
2014-08-10 |
Ангиохем Инк. |
Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の治療用の医薬の製造のためのave0010の使用
|
JP6133270B2
(ja)
|
2011-04-01 |
2017-05-24 |
マンカインド コーポレイション |
薬剤カートリッジのためのブリスター包装
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
BR112014009686A2
(pt)
|
2011-10-24 |
2018-08-07 |
Mannkind Corp |
composição analgésica inalável, pó seco e método para tratar dor
|
CN104144704B
(zh)
|
2011-11-03 |
2018-03-23 |
西兰制药公司 |
Glp‑1受体激动剂肽胃泌素缀合物
|
EP2797947B1
(en)
|
2011-12-29 |
2018-05-02 |
Novo Nordisk A/S |
Dipeptide comprising a non-proteogenic amino acid
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
AU2013289957B2
(en)
|
2012-07-12 |
2017-02-23 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
ES2754388T3
(es)
|
2013-03-15 |
2020-04-17 |
Mannkind Corp |
Composiciones y métodos de dicetopiperazina microcristalina
|
BR122019026637B1
(pt)
|
2013-07-18 |
2023-09-26 |
Mannkind Corporation |
Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
|
WO2015021064A1
(en)
|
2013-08-05 |
2015-02-12 |
Mannkind Corporation |
Insufflation apparatus and methods
|
CN104371019B
(zh)
|
2013-08-13 |
2019-09-10 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
SG11201602965WA
(en)
|
2013-10-17 |
2016-05-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
TR201902516T4
(tr)
|
2013-11-06 |
2019-03-21 |
Zealand Pharma As |
Glukagon-glp-1-gıp üçlü agonist bileşikleri.
|
EP3065706A4
(en)
|
2013-11-08 |
2017-11-29 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
JP6723921B2
(ja)
|
2014-01-09 |
2020-07-15 |
サノフイSanofi |
インスリンアナログおよび/またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
EP3212218B1
(en)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
HRP20230470T1
(hr)
|
2014-12-12 |
2023-07-21 |
Sanofi-Aventis Deutschland Gmbh |
Formulacija fiksnog omjera inzulin glargin/liksisenatid
|
KR101825048B1
(ko)
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
DK3257524T3
(da)
|
2015-02-11 |
2020-11-23 |
Gmax Biopharm Llc |
Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN107636010B
(zh)
|
2015-04-16 |
2021-10-01 |
西兰制药公司 |
酰化胰高血糖素类似物
|
CN117384274A
(zh)
|
2016-12-09 |
2024-01-12 |
西兰制药公司 |
酰化的glp-1/glp-2双重激动剂
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
CN117003874A
(zh)
|
2018-03-20 |
2023-11-07 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
CN112521501A
(zh)
|
2019-09-18 |
2021-03-19 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
BR112022013795A2
(pt)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
Composição farmacêutica líquida, e, kit
|